Akelos Inc.'s PCT International Patent Application, Licensed From Cornell University, Has Published

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, announced today that the PCT International Patent Application it has licensed from Cornell University has published.

The patent is WO2020006224A1, entitled "Substituted Alkylphenols as HCN1 Antagonists," invented by a team led by Dr. Peter Goldstein of Weill Cornell Medicine. This patent application describes and claims many novel anti-pain compounds including Akelos' present lead compound.

Akelos Inc. is in a research collaboration with Weill Cornell Medicine to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Dr. Goldstein is a scientific founder and scientific advisory board member of Akelos, Inc.

For more information, please contact:

Akelos Inc.

Dr. Steven Fox, CEO
212-953-1544
drstevefox@aol.com

About Akelos Inc.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today's most pressing areas of unmet needs.

Forward-Looking Statement

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations, and market opportunity and competition.

The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Source: Akelos Inc.

Share:


Categories: Finance

Tags: Akelos, anti-hyperalgesic, Bio-Pharmaceutical, biopharmaceutical, Chronic Pain, neuropathic pain, non-opioid treatment, Opioid Crisis, pharmaceuticals, research